Hoogendoorn M - Search Results

1

[Projections of future resource use and the costs of asthma and COPD in the Netherlands].

Hoogendoorn M, Feenstra TL, Rutten-van Mölken MP. Hoogendoorn M, et al. Ned Tijdschr Geneeskd. 2006 Jun 3;150(22):1243-50. Ned Tijdschr Geneeskd. 2006. PMID: 16796176 Dutch.

2

A dynamic population model of disease progression in COPD.

Hoogendoorn M, Rutten-van Mölken MP, Hoogenveen RT, van Genugten ML, Buist AS, Wouters EF, Feenstra TL. Hoogendoorn M, et al. Eur Respir J. 2005 Aug;26(2):223-33. doi: 10.1183/09031936.05.00122004. Eur Respir J. 2005. PMID: 16055869 Free article.

3

Is INTERdisciplinary COMmunity-based COPD management (INTERCOM) cost-effective?

Hoogendoorn M, van Wetering CR, Schols AM, Rutten-van Mölken MP. Hoogendoorn M, et al. Eur Respir J. 2010 Jan;35(1):79-87. doi: 10.1183/09031936.00043309. Epub 2009 Jul 2. Eur Respir J. 2010. PMID: 19574331 Free article. Clinical Trial.

4

Case fatality of COPD exacerbations: a meta-analysis and statistical modelling approach.

Hoogendoorn M, Hoogenveen RT, Rutten-van Mölken MP, Vestbo J, Feenstra TL. Hoogendoorn M, et al. Eur Respir J. 2011 Mar;37(3):508-15. doi: 10.1183/09031936.00043710. Epub 2010 Jul 1. Eur Respir J. 2011. PMID: 20595157 Free article.

5

Which long-acting bronchodilator is most cost-effective for the treatment of COPD?

Hoogendoorn M, Kappelhoff BS, Overbeek JA, Wouters EF, Rutten-van Mölken MP. Hoogendoorn M, et al. Neth J Med. 2012 Oct;70(8):357-64. Neth J Med. 2012. PMID: 23065983 Free article. Review.

6

Cost effectiveness of preventive interventions in type 2 diabetes mellitus: a systematic literature review.

Vijgen SM, Hoogendoorn M, Baan CA, de Wit GA, Limburg W, Feenstra TL. Vijgen SM, et al. Among authors: hoogendoorn m. Pharmacoeconomics. 2006;24(5):425-41. doi: 10.2165/00019053-200624050-00002. Pharmacoeconomics. 2006. PMID: 16706569 Review.

7

Cost-Effectiveness Models for Chronic Obstructive Pulmonary Disease (COPD): Cross-Model Comparison of Hypothetical Treatment Scenarios.

Hoogendoorn M, Feenstra T, Asukai Y, Borg S, Hansen RN, Jansson SA, Samyshkin Y, Wacker M, Briggs A, Lloyd A, Sullivan SD, Rutten-van Mölken MP. Hoogendoorn M, et al. Value Health. 2014 Nov;17(7):A557-8. doi: 10.1016/j.jval.2014.08.1836. Epub 2014 Oct 26. Value Health. 2014. PMID: 27201829 Free article. No abstract available.

8

Short- and long-term efficacy of a community-based COPD management programme in less advanced COPD: a randomised controlled trial.

van Wetering CR, Hoogendoorn M, Mol SJ, Rutten-van Mölken MP, Schols AM. van Wetering CR, et al. Among authors: hoogendoorn m. Thorax. 2010 Jan;65(1):7-13. doi: 10.1136/thx.2009.118620. Epub 2009 Aug 23. Thorax. 2010. PMID: 19703824 Clinical Trial.

9

[A patient with an extremely severe immunohaemolytic anemia due to diclofenac].

Heyning FH, Hoogendoorn M, Harvey MS, Nortier JW. Heyning FH, et al. Among authors: hoogendoorn m. Ned Tijdschr Geneeskd. 2004 Jan 3;148(1):37-9. Ned Tijdschr Geneeskd. 2004. PMID: 14750454 Dutch.

10

[Prevention of contrast nephropathy; guidelines from the Department Nephrology of the University Medical Centre Groningen].

Hemmelder MH, Hoogendoorn M, Halma C. Hemmelder MH, et al. Among authors: hoogendoorn m. Ned Tijdschr Geneeskd. 2006 Feb 4;150(5):275; author reply 275-6. Ned Tijdschr Geneeskd. 2006. PMID: 16493997 Dutch. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

235 results

Search Page